Cancer drug trial halted early: limited hope for rare tumors
NCT ID NCT03165721
First seen Feb 18, 2026 · Last updated Apr 25, 2026 · Updated 10 times
Summary
This study tested a drug called SGI-110 (guadecitabine) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, or HLRCC-related kidney cancer that had not responded to other treatments. The goal was to see if the drug could shrink tumors or slow their growth. The study was stopped early after enrolling only 9 participants, so the results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.